Objective To study the effects of oral contraceptive pills (OCP), the first-line treatment for PCOS, on high-density lipoprotein cholesterol (HDL-C) function (reverse cholesterol efflux capacity) and lipoprotein particles measured using nuclear magnetic resonance spectroscopy in obese women. Design Secondary analysis of a randomized controlled trial (OWL-PCOS) of OCP or Lifestyle (intensive Lifestyle modification) or Combined (OCP + Lifestyle) treatment groups for 16 weeks. Patients Eighty-seven overweight/obese women with PCOS at two academic centres. Measurements Change in HDL-C efflux capacity and lipoprotein particles. Results High-density lipoprotein cholesterol efflux capacity increased significantly at 16 weeks in the OCP group [0Á11; 95% confidence interval (CI) 0Á03, 0Á18, P = 0Á008] but not in the Lifestyle (P = 0Á39) or Combined group (P = 0Á18). After adjusting for HDL-C and TG levels, there was significant mean change in efflux in the Combined group (0Á09; 95% CI 0Á01, 0Á15; P = 0Á01). Change in HDL-C efflux correlated inversely with change in serum testosterone (r s = À0Á21; P = 0Á05). In contrast, OCP use induced an atherogenic low-density lipoprotein cholesterol (LDL-C) profile with increase in small (P = 0Á006) and large LDL-particles (P = 0Á002). Change in small LDL-particles correlated with change in serum testosterone (r s = À0Á31, P = 0Á009) and insulin sensitivity index (ISI; r s = À0Á31, P = 0Á02). Both Lifestyle and Combined groups did not show significant changes in the atherogenic LDL particles. Conclusions Oral contraceptive pills use is associated with improved HDL-C function and a concomitant atherogenic LDL-C profile. Combination of a Lifestyle program with OCP use improved HDL-C function and mitigated adverse effects of OCP on lipoproteins. Our study provides evidence for use of OCP in overweight/obese women with PCOS when combined with Lifestyle changes.
(LDL-C) levels are also reported to be increased in PCOS. 5, 6 Collectively, metabolic and lipid abnormalities suggest an increased risk of cardiovascular disease (CVD), although currently available risk stratification tools such as the Framingham risk score typically indicate a low 10-years risk of coronary heart disease in these women. 2 The longitudinal CARDIA study showed persistent risk of dyslipidemia over a 20-years period in women with PCOS compared with controls. 7 Although there is limited longitudinal data on the overall risk of CV events in women with PCOS 8 ; the presence of early and persistent dyslipidemia should be recognized and treated as a modifiable CV risk factor. 9 Oral contraceptives pills (OCP) are first-line therapy used to treat symptoms related to PCOS. Favourable effects of OCP on lipid profile, namely increase in HDL-C levels and potentially harmful effects from increase in TG levels, have been well described in the general population. 10, 11 Also, a few studies suggest an increased risk of myocardial infarction and stroke with prolonged use of hormonal contraceptives. 12 In a meta-analysis including 35 studies, treatment of primarily lean women with PCOS with OCP was associated with significant increase in both TG and HDL-C levels; however; there was no significant change in fasting glucose, LDL-C levels or indices of insulin resistance. 13 There is no data on long-term CV outcomes in women with PCOS treated with OCP. We recently published the OWL-PCOS study, a three-arm randomized controlled trial, and reported that overweight/obese women with PCOS treated with low-dose OCP for 4 months had an increased risk of metabolic syndrome [OR = 2Á47; 95% CI (1Á42, 4Á27)] compared to women randomized to an intensive Lifestyle modification intervention with weight loss [OR = 1Á18; 95% CI (0Á63, 2Á19)] or the combination of OCP and Lifestyle intervention [OR = 0Á72; 95% CI (0Á44, 1Á17)]. 14 Interestingly, there were no significant changes in mean serum HDL-C or LDL-C levels but a significant increase in serum TG levels after 16 weeks of treatment with OCP. We have previously demonstrated that standard lipid measurements do not always capture the lipid modulation in PCOS. 15 Despite serum HDL-C levels similar to controls, women with PCOS had decreased cholesterol efflux capacity (CEC), a marker of HDL-C function, and also exhibited an atherogenic lipid profile measured by nuclear magnetic resonance (NMR) spectroscopy. To our knowledge, advanced lipid phenotyping to assess the impact of common treatments in PCOS, such as OCP use, has not been performed. Therefore, in a secondary analysis of the OWL-PCOS study, we examined the effects of OCP treatment on HDL-C efflux capacity and compared it with an intensive Lifestyle modification intervention for weight loss and the combination of the two treatments. In addition, we used NMR spectroscopy to characterize the modulation of lipid particle composition and number in the three study arms.
Methods

OWL-PCOS trial
Stored fasting blood samples were obtained for subjects who completed 16 weeks of participation in the preconception intervention phase of the OWL-PCOS study.
14 Briefly, the trial was a randomized open-label, two-site study of three preconception treatment groups: continuous oral contraception (OCP, 20 mcg ethinyl estradiol/1 mg norethindrone acetate), an intensive Lifestyle modification program designed to produce 10% weight loss (LS), or the combination of both (OCP + LS) as described previously. 14 We randomized 149 women with BMI 27-42 kg/m 2 and 18-40 years of age with PCOS who had no major medical disorders including contraindications to sibutramine or orlistat (weight loss medication) or oral contraceptive use such as uncontrolled hypertension ≥150/100 mmHg or an abnormal EKG, and who were not taking confounding medications (sex steroids, insulin sensitizers, and other infertility drugs). We used modified Rotterdam criteria 16 to diagnose PCOS. All women had ovulatory dysfunction with either hyperandrogenism (by Ferrimen-Galwey score 17 or an elevated testosterone level 18 ) or a polycystic ovary on transvaginal ultrasound. Our Lifestyle modification (LS) program was multi-focal, and included recommendations for caloric restriction (promoted with the use of meal replacement products), increased physical activity and counselling in behavioural modification strategies. The diet was designed to create a 500-calorie deficit based on initial weight with a macronutrient profile comprising of 30% calories from protein, 45% calories from carbohydrate, and 25% calories from fat. 19 We followed the Diabetes Prevention Program recommendations for increasing physical activity (principally brisk walking or similar aerobic activity) 5 days/week. 20 To promote additional weight loss, we used a weight loss medication in those participants who were medically appropriate for usage. We began the study with sibutramine (Brand name: Meridia) at a dose of 5 mg/day and titrated up to a maximum dose of 15 mg/day if tolerated. When sibutramine was removed from the market by the Food and Drug Administration secondary to health concerns, we substituted over the counter orlistat 60 mg (Brand Name: Alli) with breakfast, lunch and dinner. Only subjects that had given written informed consent for use of their stored serum samples in secondary studies were included. University of Pennsylvania IRB approval was obtained to utilize the deidentifed samples. We have also published the main outcomes for the OWL-PCOS Study 14 and the protocol and case report forms can be accessed at: http://ctsi. psu.edu/owl-pcos/. The trial was registered at Clinicaltrials.gov (OWL PCOS: NCT00704912).
Serum assays. Glucose and insulin levels were measured at the Penn State College of Medicine. Estimation of total testosterone (T) and sex hormone-binding globulin (SHBG) levels was performed at the Core Ligand Laboratory at the University of Virginia. These assays had interassay coefficients of variation (CV) of <10%, including the T assay, which was optimized by increasing the sample volume to reproducibly measure T levels in the female range.
16 weeks. Six subjects were excluded from the study for baseline triglyceride level ≥2Á26 mmol/l or baseline HDL level 1Á68 mmol/l determination. HDL CEC was measured by a validated ex vivo system involving the incubation of macrophages with apolipoprotein B-depleted serum from subjects. 15 A total of 774 cells, derived from a murine macrophage cell line, were plated and radiolabelled with 74 kBq of 3 H-cholesterol per millilitre. ABCA1 was upregulated by means of a 6-h incubation with 0Á3 mM 8-(4-chlorophenylthio)-cyclic AMP. Subsequently, efflux mediums containing 2Á8% apolipoprotein B-depleted serum were added for 4 h. To prepare Apo-B-depleted serum, samples were thawed prior to Apo-B precipitation. Briefly, 40 parts polyethylene glycol solution (PEG; 20% PEG 8000 MW in 200 mM glycine buffer, pH 7Á4) was added to 100-parts serum and mixed by pipetting and then incubated at room temperature for 20 min before spinning in a microcentrifuge at 9390 g for 30 min at 4°C. Apo-B-containing lipoproteins are pelleted by this procedure, and the supernatant, which contains the HDL fraction, is recovered and diluted in 14 mM MEM-HEPES (no bicarbonate) + 0Á15 mM cAMP to 2Á8% (equivalent to 2% serum). All steps were performed in the presence of the acylcoenzyme A cholesterol acyltransferase inhibitor CP113,818 (2 lg/ml). Liquid scintillation counting was used to quantify the efflux of radioactive cholesterol from the cells. The quantity of radioactive cholesterol incorporated into cellular lipids was calculated by means of isopropanol extraction of control wells not exposed to patient serum. Efflux was calculated by using the following formula: (lCi of 3H-cholesterol in media containing 2Á8% apoB-depleted subject plasma-lCi of 3H-cholesterol in plasma-free media/lCi of 3H-cholesterol in media containing 2Á8% apoB-depleted pooled control plasma-lCi of 3H-cholesterol in pooled control plasma-free media). All assays were performed in duplicate. The inter-and intra assay coefficients of variation for the HDL Efflux assay was <10%. Lipoprotein subclass particle concentrations [HDL-P, LDL-P and very large LDL particles (VLDL-P)] and average diameters (in nanometers) were measured using an automated NMR spectroscopy at the NIH Clinical laboratory (Vantera, Labcorp, Burlington, NC, USA). 21 Particle concentrations of the differentsized lipoprotein subclasses were derived from the measured amplitudes of the characteristic lipid methyl group NMR signals they emit. Subclasses were summed to provide concentrations of total LDL-P, total HDL-P and total VLDL-P. Mean LDL-P and HDL-P sizes are weighted-averages (i.e., the diameter of each subclass multiplied by its relative concentration.)'.
Statistical analysis
Groups were compared at baseline using exact chi-square test, ANOVA, or Kruskal-Wallis test as appropriate. A linear mixedeffect model was used to assess changes from baseline within each group and to compare the changes between the groups. Changes from this model are reported as a mean difference and 95% confidence interval (CI), with the exception of testosterone which was log-transformed and therefore the change represents a ratio of geometric means. HDL and TG were included as time-varying covariates in the model where efflux was measured as outcome. Spearman correlation coefficients (r s ) were used to assess the association between baseline lipoprotein parameters, as well as the changes in efflux and lipoproteins with the changes in weight, testosterone and insulin sensitivity index (ISI).
Results Table 1 shows the baseline characteristics for subjects included in this study. There were no significant differences between the three groups for age and BMI and the diagnostic characteristics of PCOS such as clinical and biochemical hyperandrogenism and polycystic ovary morphology. At baseline, the HDL-C efflux in the OCP group was significantly higher than that in the Combined group [difference of adjusted means = 0Á09; 95% CI 0Á03, 0Á16, P = 0Á005 (Fig. 1)] . There was no difference between Lifestyle and either the OCP or Combined groups. At baseline, HDL-C efflux positively correlated with HDL-C [r s = 0Á69; 95% CI (0Á54, 0Á80); P < .0001] and total HDL-P [r s = 0Á70; 95% CI (0Á56, 0Á81); P < .0001]. The mean change in HDL-C efflux capacity from baseline to the 16 weeks visit in the OCP group was 0Á11; 95% CI (0Á03, 0Á18); P = 0Á008, in the Lifestyle group was 0Á04; 95% CI (À0Á01, 0Á11); P = 0Á39, and in the Combined group was 0Á06; 95% CI (À0Á03, 0Á15); P = 0Á18. Figure 1 shows the change in efflux on adjusting for HDL-C and TG in the OCP group [mean change = 0Á05; 95% CI (0Á03, 0Á18); P = 0Á13], Lifestyle group [mean change = 0Á03; 95% CI (À0Á04, 0Á08); P = 0Á48] and Combined group [mean change = 0Á09; 95% CI (0Á01, 0Á15); P = 0Á01]. There was a significant decrease in mean BMI over the 16-weeks period in both the Lifestyle group [mean change = À2Á3; 95% CI (À2Á7, À1Á8); P < 0Á001] and Combined group [mean change = À2Á6; 95% CI (À3Á2, À2Á1); P < 0Á001] but not in the OCP group [mean change = À0Á4; 95% CI À0Á9, 0Á0); P = 0Á08]. Correspondingly, there was significant improvement in the ISI in the Lifestyle group [mean change = 1Á3; 95% CI (1Á1, 1Á5); P < .0001] and Combined group [mean change = 1Á2; 95% CI (1Á0, 1Á4); P = 0Á03] but not in the OCP group [mean change = 0Á9; 95% CI (0Á8, 1Á0); P = 0Á11]. As expected, there was a significant decrease in testosterone levels in the OCP group [ratio of geometric means = 0Á4; 95% CI (0Á3, 0Á5); P < 0Á001] and Combined group [ratio of geometric means = 0Á4; 95% CI (0Á4, 0Á5); P < 0Á001] but not in the Lifestyle group [ratio of geometric means = 0Á9; 95% CI (0Á8, 1Á1); P = 0Á30]. Change in HDL-C efflux inversely correlated with change in serum testosterone levels [r s = À0Á21; 95% CI (À0Á40, 0Á00); P = 0Á05] but not change in BMI [r s = 0Á19; 95% CI (À0Á03, 0Á38); P = 0Á09] or change in ISI [r s = À0Á02; 95% CI (À0Á26, 0Á23); P = 0Á89]. Table 2 shows baseline serum lipoprotein values, and there were no significant differences between groups. There was a positive correlation between baseline HDL-C and total HDL-P (r s = 0Á85, P < .0001), LDL-C and total LDL-P (r s = 0Á88, P < .0001), and TG and total VLDL-P (r s = 0Á70, P < .0001). Figure 2 shows change in mean levels in lipoprotein particle size and numbers in all three groups after treatment for 16 weeks. Corresponding to the increase in HDL-C efflux, OCP use for 16 weeks was associated with a significant increase in total HDL-P including small HDL-P (P = 0Á04) and decrease in HDL-P size (P = 0Á004) compared to baseline. Also, total LDL-P including small LDL-P (P = 0Á006) and large LDL-P (P = 0Á002) increased with a corresponding decrease in LDL-P size (P = 0Á04) with OCP use. There were no significant changes in VLDL-P with OCP treatment. The Lifestyle and Combined groups did not show significant changes in HDL-P and LDL-P or their size compared to baseline after 16 weeks of intervention. The change in HDL-P size was significantly different in the OCP group vs that in the Lifestyle group (P = 0Á02) as was the change in LDL-P size (P = 0Á02). The OCP group had a significant increase in small LDL-P compared with that in the Lifestyle group (P = 0Á03), and large LDL-P was significantly increased in the OCP vs Combined group (P = 0Á01). Changes in lipoprotein particle concentrations and size were not significantly different between the Lifestyle and Combined groups.
The changes in lipoprotein concentrations and size associated with changes in BMI, testosterone, and ISI in all three treatment groups are shown in Table 3 . Change in small LDL-P inversely correlated with change in testosterone (r s = À0Á31; P = 0Á01) and ISI (r s = À0Á31; P = 0Á02) while change in LDL-P size positively correlated with change in testosterone (r s = 0Á26; P = 0Á03) and inversely correlated with change in glucose area under the curve (AUC; r s = À0Á55; P < .001, data not shown in table). Change in ISI was inversely significantly correlated with change in large-medium VLDL-P (r s = À0Á30; P = 0Á02), change in large VLDL-P (r s = À0Á33; P = 0Á01), change in medium VLDL-P (r s = À0Á29; P = 0Á03), and change in VLDL-P size (r s = À0Á34; P = 0Á01). There were also significant positive associations of change in small VLDL-P with change in testosterone (r s = 0Á25; P = 0Á04) and change in VLDL-P size with change in BMI (r s = 0Á28; P = 0Á03). Additionally, change in BMI was There are no significant differences between groups. *Median (25th percentile, 75th percentile). positively correlated with change in large-medium HDL-P (r s = 0Á26; P = 0Á03) and medium HDL-P (r s = 0Á30; P = 0Á01).
Discussion
Our study demonstrates for the first time that oral combined hormonal contraceptives used at a low dose (20 mcg ethinyl estradiol) for 16 weeks are associated with significant increase in CEC. Moreover, OCP use also significantly increased HDL-P levels measured by NMR spectroscopy, although HDL-C levels only showed a modest increase using standard lipid assays. 14 The Combined group also showed significant increase in CEC after adjusting for HDL-C and TG levels. In contrast, OCP use alone resulted in significant increase in LDL-P, especially small LDL-P, suggesting an unfavourable atherogenic effect especially in this high-risk population. These effects were ameliorated with the addition of Lifestyle changes as seen in the Combined group providing evidence for the use of OCP with Lifestyle changes in overweight/obese women with PCOS. Studies in both pre-and post-menopausal women have demonstrated that oestrogen increases serum HDL-C levels measured using standard lipid assays. 13, 22 Lower doses of oral oestrogen as used in hormone replacement therapy regimens are also associated with an increase in HDL-C levels. 23 To our knowledge, our study is the first to demonstrate an increase in HDL-C function as determined by CEC with use of OCP. Our findings may be primarily related to an increase in HDL-C levels. One previous study has examined the role of endogenous estradiol status (pre-and post-menopausal) and gender on reverse cholesterol efflux and did not report any significant differences between the groups. 24 In contrast, in healthy women with normal lipid profile compared to age matched males, scavenger receptor (SR)-B1-mediated CEC was found to be significantly higher. 25 The authors reported that the increased cholesterol efflux in women in their study was associated with levels of serum HDL-C > 1Á42 mmol/l. Physiological and supraphysiological doses of testosterone have also been reported to increase expression of SR-B1 in vitro using a human hepatocyte cell line and macrophages 26 and ethinyl estradiol increased SR-B1 expression in rat hepatocytes. 27 In one study, 6-months treatment of male to female transgenders with high doses of estradiol showed a significant increase in HDL-C levels but interestingly no change in cholesterol acceptor capacity was observed. 28 Other potential mechanisms for the effects of oestrogen include a decrease in hepatic lipase associated with an increase in Apo A1-associated HDL-C. 29, 30 The mechanism by which exogenously administrated oestrogen, via OCP, increases CEC is however unclear and could be related to the proposed actions of oestrogen on hepatic lipase or secondary to a decrease in serum androgens as noted in our study.
In a large meta-analysis, use of OCP for at least 3 months in women with PCOS significantly increased TG levels but not LDL-C levels measured by standard lipid assays. 13 We have previously shown that women with PCOS demonstrated an atherogenic lipid profile comprising of increase VLDL-P and small LDL-P, independent of obesity, when measured by NMR spectroscopy. 15 It is unclear whether hyperandrogenemia, insulin resistance or inflammation associated with PCOS could explain our original findings of atherogenic dyslipidemia in PCOS. 31, 32 In the Framingham Heart Study, the number of small LDL particles was elevated in subjects with metabolic syndrome 33 We reported an increase in metabolic syndrome after 16-weeks OCP use in the OWL-PCOS study 14 and our current results clearly indicate atherogenic changes as measured by NMR spectroscopy in the same group. Although it has been speculated that androgens may be associated with dyslipidemia by influencing central body fat distribution, increasing hepatic lipase activity, and exacerbating insulin resistance, 34 in our study total testosterone levels were significantly lowered after use of OCP and cannot explain the increase in LDL-P. Longitudinal studies will better quantify the cumulative CV risk of the paradoxical effects of OCP on lipoproteins in women with PCOS. Modest weight loss in women with PCOS is associated with improvements in reproductive function with no significant changes in lipid profiles. 35 In our study, Lifestyle modification intervention alone was associated with a 6-7% weight loss but did not demonstrate a significant impact on either CEC or 
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Clinical Endocrinology (2017), 86, 739-746 lipoprotein particle concentrations and size. Our findings differ from other studies that show decreased CEC after modest weight loss in obese subjects. 36, 37 In fact, the Combined arm of our study showed a significant improvement in HDL-C efflux. Furthermore, our study suggests that combining Lifestyle modifications with OCP use in obese PCOS women may be the best therapeutic intervention, as it decreased VLDL-P and did not increase LDL-P concentrations. The strengths of our study include randomization to three commonly used interventions, measurement of lipid parameters using NMR spectroscopy, measurement of HDL-C function and no use of cholesterol lowering agents. Our results are generalizable 
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to an obese PCOS population which represents a significant majority of women with this condition in the United States. The limitations of our study include that we performed a secondary analysis of a randomized clinical trial that was not designed a priori to assess the impact of the selected interventions on lipid profiles and CEC. It is not clear whether other doses of ethinyl estradiol and different types of progestins will have similar effects. The duration of the intervention was short, and replication studies should include longer duration of OCP use. Our study demonstrated that use of OCP in an overweight/obese PCOS population results in varying effects on lipids including atherogenic lipoprotein changes, i.e., an increase in LDL-P concentrations but yet, beneficial increases in HDL-C efflux capacity. The long-term cardiovascular impact of these lipid changes in this high-risk population is currently unclear; however, results from two recent studies indicate that HDL-C function may be a better marker of CV outcomes independent of HDL-C levels. 38, 39 For example, HDL-C function but not HDL-C levels has been inversely associated with incident CV events as shown in a cohort from the Dallas Heart study (n = 2927). These authors showed a 67% reduction in incident CV events when comparing highest quartile of HDL-C efflux with lowest quartile at baseline. Our findings may provide insights into the controversies regarding the overall impact of OCP on cardiovascular risk in young women in the general population. However, these findings need to be replicated in studies including larger numbers of subjects using OCP for a longer duration. In the meantime as addition of caloric restriction and exercise clearly improved CEC and ameliorated the adverse lipoprotein changes associated with OCP therapy alone, this should be the preferred treatment in obese women with PCOS.
Funding source
